Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

January 14, 2021
Rebecca L. Olin, MD, MSCE

Supplements And Featured Publications, Updates in Relapsed/Refractory AML, Volume 1, Issue 1

Partner | Cancer Centers | <b>UCSF Helen Diller Family Comprehensive Cancer Center</b>

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia (AML).

Inhibiting menin appears to provide benefit in patients with MLL translocations, as well as those with NPM1 mutations. Historically, these subgroups of patients with AML, particularly those with MLL translocations, have been difficult to treat, Olin says.

As such, novel menin inhibitors are being evaluated in ongoing clinical trials, Olin says. For example, the investigational agent KO-539 is being examined in the ongoing, first-in-human KOMET-001 study (NCT04067336) for patients with relapsed/refractory AML.


x